Idelalisib的合成研究进展  

Research Progress on Synthesis of Idelalisib

作　　者：龚雅挺 GONG Ya-ting(Zhejiang LEPU Pharmaceutical Co.,Ltd.,Zhejiang Taizhou 318000,China)

机构地区：[1]浙江乐普药业股份有限公司,浙江台州318000

出　　处：《广州化工》2019年第2期14-15,27,共3页GuangZhou Chemical Industry

摘　　要：Idelalisib是全球首个高选择性口服磷脂酰肌醇3-激酶delta(PI3K-δ)抑制剂。Idelalisib本身并不能杀死癌细胞,其疗效主要来自于改变肿瘤细胞的免疫环境。近年来虽然发展了多条合成路线,但都存在着一定的局限性,比如需要高温、无水体系等苛刻的反应条件;用到大量的金属试剂及一些价格昂贵的试剂;需要大量的反应溶剂;反应收率低;提纯困难等等。本文主要对Idelalisib近年来的研究进展做一个综述。Idelalisib is the first highly selective oral phosphatidyl inositol 3-kinase delta inhibitor.Idelalisib can change the immune environment of cancer cells but can t kill them by itself.In recent years,several synthetic routes have been developed,but there are certain limitations,such as high temperature,anhydrous system,using a lot of metal reagents,expensive reagents and solvent,low yield,hard to be purified.The research progress on synthesis of Idelalisib was reviewed.

关 键 词：Idelalisib 喹唑啉酮 合成 

分 类 号：R979.14[医药卫生—药品]